Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under X4 Pharmaceuticals, Inc in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Kelly Gold, Director (Form 8-K filed 2026-07-01). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Venrock Healthcare Capital Partners Iii, L.P. (filed 2026-09-21).
Who is behind it
X4 Pharmaceuticals, Inc: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-07).
Officers and directors, each with the role and the filing that names them:
- Adam Craig: Executive Officer, Director (Form D, 2025-08-25)
- John Volpone: Executive Officer (Form D, 2025-08-25)
- Christophe Arbet-Engels: Executive Officer (Form D, 2025-08-25)
- Mark Baldry: Executive Officer (Form D, 2025-08-25)
- Mary DiBiase: Executive Officer (Form D, 2025-08-25)
- David Kirske: Executive Officer (Form D, 2025-08-25)
- Gary J. Bridger: Director (Form D, 2025-08-25)
- Francoise De Craecker: Director (Form D, 2025-08-25)
- Murray W. Stewart: Director (Form D, 2025-08-25)
- Michael S. Wyzga: Director (Form D, 2025-08-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Fmr LLC | 4.6% |
| Schedule 13G, 2026-09-21 | Venrock Healthcare Capital Partners Iii, L.P. | 5.6% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 8.33% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 8.1% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 5.9% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 7.3% |
| Schedule 13G/A, 2026-03-06 | Morgan Stanley | 10.2% |
| Schedule 13G/A, 2026-02-17 | Trails Edge Capital Partners, LP | 5.8% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-01 | Kelly Gold | Director | appointed | 2026-07-01 |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-08-25 | $85M | $85M |
| Form D, 2023-06-01 | $65.02M | $65.02M |
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/x4-pharmaceuticalsLast updated 2026-10-18
Primary record: Schedule 13G, 2026-09-21 · Form D, 2025-08-25 · Form 8-K, 2026-07-01 · Form D, 2023-06-01
Who owns X4 Pharmaceuticals, Inc? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/x4-pharmaceuticals